UY27906A1 - Inhibidores de quinasas - Google Patents

Inhibidores de quinasas

Info

Publication number
UY27906A1
UY27906A1 UY27906A UY27906A UY27906A1 UY 27906 A1 UY27906 A1 UY 27906A1 UY 27906 A UY27906 A UY 27906A UY 27906 A UY27906 A UY 27906A UY 27906 A1 UY27906 A1 UY 27906A1
Authority
UY
Uruguay
Prior art keywords
methods
kinase inhibitors
dihydropyrimidopyrimidines
pyridopyrazines
pyrimidopyrimidines
Prior art date
Application number
UY27906A
Other languages
English (en)
Inventor
Cleo J Chivikas Connolly
Christopher James Deur
James Marino Hamby
Denton Wade Hoyer
Chris Limberakis
Jessica Elizabeth Reed
Med Conrad Schroeder
Clarke Bentley Taylor
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of UY27906A1 publication Critical patent/UY27906A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Esta invención proporciona pirimidopirimidinas, dihidropirimidopirimidinas, piridopirimidinas, naftiridinas y piridopirazinas fenil sustituidas de fórmula general :que inhiben las enzimas quinasa y tirosinaquinasa dependientes de la ciclina, los procedimientos y compuestos intemedios para su síntesis, así como composiciones farmacéuticas y procedimientos para su uso en tratamiento, inhibición o prevención de enfermedades asociadas con trastornos de proliferación celular, que incluyen angiogénesis, aterosclerosis, reestenosis y cáncer.
UY27906A 2002-07-25 2003-07-24 Inhibidores de quinasas UY27906A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39863802P 2002-07-25 2002-07-25

Publications (1)

Publication Number Publication Date
UY27906A1 true UY27906A1 (es) 2004-02-27

Family

ID=31188438

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27906A UY27906A1 (es) 2002-07-25 2003-07-24 Inhibidores de quinasas

Country Status (18)

Country Link
US (1) US7196090B2 (es)
EP (1) EP1549651B1 (es)
JP (1) JP2005538992A (es)
AR (1) AR040513A1 (es)
AT (1) ATE452891T1 (es)
AU (1) AU2003249442A1 (es)
BR (1) BR0312867A (es)
CA (1) CA2493633C (es)
DE (1) DE60330694D1 (es)
ES (1) ES2335659T3 (es)
GT (1) GT200300150A (es)
HN (1) HN2003000227A (es)
MX (1) MXPA05000814A (es)
PA (1) PA8577501A1 (es)
PE (1) PE20040688A1 (es)
TW (1) TW200413375A (es)
UY (1) UY27906A1 (es)
WO (1) WO2004011465A1 (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236048B2 (en) * 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
JP4214729B2 (ja) * 2002-07-25 2009-01-28 コニカミノルタホールディングス株式会社 硬化性白インク組成物
US7084270B2 (en) 2002-08-14 2006-08-01 Hoffman-La Roche Inc. Pyrimido compounds having antiproliferative activity
US7112676B2 (en) * 2002-11-04 2006-09-26 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
BRPI0409366A (pt) * 2003-04-10 2006-04-25 Hoffmann La Roche compostos de pirimido
GB0313511D0 (en) * 2003-06-11 2003-07-16 Cyclacel Ltd Combination
AU2004260689B8 (en) * 2003-07-29 2008-05-15 Irm Llc Compounds and compositions as protein kinase inhibitors
TW200526224A (en) * 2003-12-22 2005-08-16 Alcon Inc Short form c-Maf transcription factor antagonists for treatment of glaucoma
EP1789417A1 (en) * 2004-08-31 2007-05-30 F.Hoffmann-La Roche Ag AMIDE DERIVATIVES OF 7-AMINO-3-PHENYL-DIHYDROPYRIMIDO [4,5-d]PYRIMIDINONES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS
RU2007111757A (ru) 2004-08-31 2008-10-10 Ф.Хоффманн-Ля Рош Аг (Ch) Амидные производные 3-фенилдигидропиримидо [4,5-d] пиримидинонов, их получение и использованиев качестве фармацевтических агентов
WO2006038112A1 (en) * 2004-10-01 2006-04-13 Warner-Lambert Company Llc Use of kinase inhibitors to promote neochondrogenesis
FR2876584B1 (fr) * 2004-10-15 2007-04-13 Centre Nat Rech Scient Cnrse Utilisation de la kenpaullone pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
JP5271697B2 (ja) * 2005-03-23 2013-08-21 アボット ラボラトリーズ 医療装置を介する高親油性薬剤の送達
EP1931667A1 (en) * 2005-09-28 2008-06-18 Ranbaxy Laboratories Limited Pyrido-pyridimidine derivatives useful as antiinflammatory agents
DK1954697T3 (da) * 2005-10-21 2010-06-14 Glaxo Group Ltd Peri-kondenserede tricykliske forbindelser, der er anvendelige som antibakterielle midler
CA2633768A1 (en) * 2005-11-10 2007-05-18 Bayer Schering Pharma Aktiengesellschaft Reduction of restenosis
CA2630463C (en) * 2005-11-21 2015-01-06 Anadys Pharmaceuticals, Inc. Novel process for the preparation of 5-amino-3h-thiazolo[4,5-d]pyrimidin-2-one
EP1963324B1 (en) 2005-12-22 2010-04-21 Glaxo Group Limited Heterocyclic compounds, their preparation and their use as antibacterials
CA2636981A1 (en) 2006-01-31 2007-08-09 F. Hoffmann-La Roche Ag 7h-pyrido[3,4-d]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors
US7897762B2 (en) * 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
MX2009003658A (es) 2006-10-05 2009-04-22 Cv Therapeutics Inc Compuestos heterociclicos que contienen nitrogeno biciclico para utilizarse como inhibidores de desaturasa de estearoilo-coa.
US7893066B2 (en) 2006-10-05 2011-02-22 Gilead Palo Alto, Inc. Pyridol[2,3-B]pyrazinones for use as stearoyl CoA desaturase inhibitors
CN101535308A (zh) * 2006-11-09 2009-09-16 霍夫曼-拉罗奇有限公司 作为激酶抑制剂的取代的6-苯基-吡啶并[2，3-d]嘧啶-7-酮衍生物及其使用方法
US8131527B1 (en) 2006-12-22 2012-03-06 Astex Therapeutics Ltd. FGFR pharmacophore compounds
US8513276B2 (en) 2006-12-22 2013-08-20 Astex Therapeutics Limited Imidazo[1,2-a]pyridine compounds for use in treating cancer
US8895745B2 (en) * 2006-12-22 2014-11-25 Astex Therapeutics Limited Bicyclic heterocyclic compounds as FGFR inhibitors
CA2681560A1 (en) * 2007-04-09 2008-10-16 Cv Therapeutics, Inc. Pteridinone derivatives for use as stearoyl coa desaturase inhibitors
US20100160339A1 (en) * 2007-05-21 2010-06-24 Mayo Foundation For Medical Education And Research Treating pancreatitis
DK2168966T3 (en) * 2007-06-15 2017-01-23 Msd Kk BICYCLOANILIN DERIVATIVES
WO2009016486A2 (en) * 2007-08-02 2009-02-05 Compugen, Ltd Use of nmda receptor antagonists for treatment of urologic tumors
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
BRPI0908849A2 (pt) * 2008-02-22 2015-08-25 Irm Llc Composto e composições como c-kit e inibidores de pdgfr quinase
JP2011516546A (ja) * 2008-04-10 2011-05-26 ギリアード サイエンシーズ， インコーポレイテッド ステアロイル−ＣｏＡデサチュラーゼのインヒビターとして使用するための二環式窒素含有複素環化合物
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
US20100267752A1 (en) * 2008-10-15 2010-10-21 Gilead Palo Alto, Inc. 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
CA2745970A1 (en) 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivative
WO2010067888A1 (en) * 2008-12-12 2010-06-17 Banyu Pharmaceutical Co.,Ltd. Dihydropyrimidopyrimidine derivatives
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
US8663210B2 (en) 2009-05-13 2014-03-04 Novian Health, Inc. Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
EP2827869A4 (en) 2012-03-23 2015-09-23 Dennis Brown COMPOSITIONS AND METHODS FOR IMPROVING THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ITS ANALOGUES INCLUDING MESOINDIGO
ME02651B (me) 2012-06-13 2017-06-20 Incyte Holdings Corp Substituisana triciklična jedinjenja kao inhibitori fgfr
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
MY181020A (en) 2013-03-15 2020-12-16 Sanofi Sa Heteroaryl compounds and uses thereof
US9321786B2 (en) 2013-03-15 2016-04-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
PE20151776A1 (es) * 2013-03-15 2015-12-11 Celgene Avilomics Res Inc Compuestos de heteroarilo y sus usos
CA2909207C (en) 2013-04-19 2021-11-02 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
RU2715236C2 (ru) 2014-03-26 2020-02-26 Астекс Терапьютикс Лтд Комбинации
AU2015296322B2 (en) 2014-07-26 2019-09-19 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as CDK inhibitors and uses thereof
AU2015329625B2 (en) 2014-10-10 2018-04-05 Pfizer Inc. Synergistic auristatin combinations
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CN104478742A (zh) * 2014-11-24 2015-04-01 苏州乔纳森新材料科技有限公司 一种氟代化合物及其制备方法
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
CR20170390A (es) 2015-02-20 2017-10-23 Incyte Holdings Corp Heterociclos biciclicos como inhibidores de fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
ES2876411T3 (es) * 2016-08-15 2021-11-12 Pfizer Inhibidores de piridopirimdinona CDK2/4/6
GB201703881D0 (en) 2017-03-10 2017-04-26 Almac Discovery Ltd Pharmaceutical compounds
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN109836427B (zh) * 2017-11-29 2022-04-15 暨南大学 嘧啶并嘧啶酮类化合物及其应用
BR112020022373A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation sais de um inibidor de fgfr
WO2019213544A2 (en) 2018-05-04 2019-11-07 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
EA202191800A1 (ru) * 2018-12-27 2021-09-13 Ле Лаборатуар Сервье Сас Азагетеробициклические ингибиторы мат2а и способы их применения для нацеливания на рак
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JOP20220083A1 (ar) 2019-10-14 2023-01-30 Incyte Corp حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
JP2023505258A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
TW202313611A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2949466A (en) * 1958-03-04 1960-08-16 Parke Davis & Co Pyrimidine compounds and means of producing the same
US3912723A (en) * 1971-03-29 1975-10-14 Pfizer 2-Phenyl-as-triazine-3,5(2H,4H)diones
US4425346A (en) * 1980-08-01 1984-01-10 Smith And Nephew Associated Companies Limited Pharmaceutical compositions
JPS60226882A (ja) * 1984-04-24 1985-11-12 Nippon Zoki Pharmaceut Co Ltd 新規ピリミドピリミジン誘導体
US5654307A (en) * 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
AU701127B2 (en) 1994-10-27 1999-01-21 Merck & Co., Inc. Muscarine antagonists
ATE190978T1 (de) 1994-11-14 2000-04-15 Warner Lambert Co 6-aryl-pyrido(2,3-d)pyrimidine und -naphthyridine zur hemmung der durch protein-tyrosin-kinase hervorgerufenen zellvermehrung
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
DK0892789T4 (da) 1996-04-12 2010-04-06 Warner Lambert Co Irreversible inhibitorer af tyrosin kinaser
JP4965021B2 (ja) * 1997-08-20 2012-07-04 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー プロテインチロシンキナーゼおよび細胞周期キナーゼ仲介細胞増殖を阻害するためのナフチリジノン
HUP0102514A3 (en) 1998-05-26 2002-03-28 Warner Lambert Co Pyrido-pyrimidin and pyrimido-pyrimidin derivatives as inhibitors of cellular proliferation and pharmaceutical compositions thereof
WO2000024744A1 (en) 1998-10-23 2000-05-04 F. Hoffmann-La Roche Ag Bicyclic nitrogen heterocycles
AP2002002479A0 (en) * 1999-09-15 2002-06-30 Warner Lambert Co Pteridinones as kinase inhibitors.
AU776695B2 (en) 1999-10-21 2004-09-16 F. Hoffmann-La Roche Ag Alkylamino substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase
PL357502A1 (en) 1999-10-21 2004-07-26 F.Hoffmann-La Roche Ag Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase
MY141144A (en) 2000-03-02 2010-03-15 Smithkline Beecham Corp 1, 5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-dipyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
ES2311532T3 (es) * 2000-08-04 2009-02-16 Warner-Lambert Company Llc 2-(4-pirdil)amino-6-dialcoxifenil-pirido(2.3-d)pirimidin-7-onas.
ES2248233T3 (es) * 2000-08-04 2006-03-16 Warner-Lambert Company Llc Procedimiento de preparacion de 2-(4-piridil)amino-6-dialquiloxifenil-pirido(2,3-d)pirimidin-7-onas.
WO2002012237A2 (en) * 2000-08-04 2002-02-14 Warner-Lambert Company Process for preparing 2-(4-pyridyl)amino-6-dialkyloxyphenyl-pyrido[2,3-d]pyrimidin-7-ones

Also Published As

Publication number Publication date
AR040513A1 (es) 2005-04-06
TW200413375A (en) 2004-08-01
PA8577501A1 (es) 2004-02-07
CA2493633A1 (en) 2004-02-05
ATE452891T1 (de) 2010-01-15
WO2004011465A1 (en) 2004-02-05
US20040019210A1 (en) 2004-01-29
ES2335659T3 (es) 2010-03-31
MXPA05000814A (es) 2005-04-19
DE60330694D1 (de) 2010-02-04
HN2003000227A (es) 2005-10-20
EP1549651A1 (en) 2005-07-06
AU2003249442A1 (en) 2004-02-16
JP2005538992A (ja) 2005-12-22
GT200300150A (es) 2004-06-08
BR0312867A (pt) 2005-06-14
US7196090B2 (en) 2007-03-27
EP1549651B1 (en) 2009-12-23
PE20040688A1 (es) 2004-10-06
CA2493633C (en) 2009-04-07

Similar Documents

Publication Publication Date Title
UY27906A1 (es) Inhibidores de quinasas
CL2011000489A1 (es) Compuestos derivados de pirimido[5,4-d]pirimidina, los cuales actuan como inhibidores de tirosina-quinasas; y composiciones farmaceuticas que los comprenden, utiles en el tratamiento de enfermedades que se caracterizan por una proliferacion celular excesiva o anomala
DK1537116T3 (da) Pyrazolopyrimidiner egnede til behandling af cancersygdomme
ECSP055899A (es) Pirimidinas inhibidoras de chk, pdk y akt, su producción y su uso como agentes farmacéuticos
ECSP088450A (es) Derivados de pirimidina 4-(3-aminopirazol) para uso como inhibidores de tirosina quinasa en el tratamiento de cáncer
CU23778B7 (es) Pirrolopirazoles, inhibidores potentes de quinasa
PA8675701A1 (es) Nuevos derivados del fluoreno, composiciones que los contienen y su utilización
CL2011001215A1 (es) Compuestos derivados de pirimidina, inhibidores de tirosina quinasa; composiciones farmaceuticas que los comprenden; y su uso en el tratamiento y/o prevencion de cancer, enfermedades inflamatorias y enfermedades autoinmunes.
HK1112233A1 (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors for the treatment of cancer
BRPI0607346A2 (pt) compostos inibidores de raf e métodos
ECSP066763A (es) Pirazolopirimidinas novedosas como inhibidores de quinasa ciclina-dependientes
DE60309848D1 (de) Purinderivate als kinaseinhibitoren
TW200745127A (en) Pyrazolopyrimidines as protein kinase inhibitors
ECSP11010904A (es) Compuestos de pirrolo[2,3-d]pirimidina
BRPI0513915A (pt) compostos aminoeteroarila enantiomericamente puros como inibidores de proteìna quinase
TW200745123A (en) Pyrazolopyrimidines as protein kinase inhibitors
ECSP088145A (es) Derivados bicíclicos como inhibidores de la cinasa p38
MX2009011355A (es) Nuevas pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas.
CU23218A3 (es) Derivados espirociclicos nuevos y su uso como inhibidores de fosfodiesterasa - 7
CL2007001996A1 (es) Compuestos derivados de heteroarilos nitrogenados sustituidos con fenilo, inhibidores de la produccion de citoquinas; composicion farmaceutica que los comprende; y sus usos en el tratamiento del cancer, infecciones, enfermedades inflamatorias y autoinmunes.
CU23464B7 (es) (1,8)naftidirin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia
ECSP088345A (es) Nuevas pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina
ATE378321T1 (de) Pyrazolopyrimidine
DK1791830T3 (da) Diaminotriazol-forbindelser der er nyttige som protein-kinase-inhibitorer
ZA200609637B (en) 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150126